Literature DB >> 19519492

Drug treatment of obesity: established and emerging therapies.

M Luisa Isidro1, Fernando Cordido.   

Abstract

Available anti-obesity pharmacotherapy options remain very limited. The development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake, by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacological treatment options.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519492     DOI: 10.2174/138955709788452739

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  8 in total

1.  Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications.

Authors:  Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  Int J Pept       Date:  2010-02-09

2.  Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes.

Authors:  Pratibha V Nerurkar; Yun-Kung Lee; Vivek R Nerurkar
Journal:  BMC Complement Altern Med       Date:  2010-06-29       Impact factor: 3.659

3.  Follistatin promotes adipocyte differentiation, browning, and energy metabolism.

Authors:  Melissa Braga; Srinivasa T Reddy; Laurent Vergnes; Shehla Pervin; Victor Grijalva; David Stout; John David; Xinmin Li; Venina Tomasian; Christopher B Reid; Keith C Norris; Sherin U Devaskar; Karen Reue; Rajan Singh
Journal:  J Lipid Res       Date:  2014-01-17       Impact factor: 5.922

Review 4.  Regulation of brown adipocyte metabolism by myostatin/follistatin signaling.

Authors:  Rajan Singh; Melissa Braga; Shehla Pervin
Journal:  Front Cell Dev Biol       Date:  2014-10-16

5.  Pyrazoles and Pyrazolines as Anti-Inflammatory Agents.

Authors:  Martha Mantzanidou; Eleni Pontiki; Dimitra Hadjipavlou-Litina
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

6.  Carbonic Anhydrase Inhibition with Sulfonamides Incorporating Pyrazole- and Pyridazinecarboxamide Moieties Provides Examples of Isoform-Selective Inhibitors.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Mariana Pinteala; Volodymyr Brovarets; Roman Vydzhak; Svitlana Panchishin; Athina Geronikaki; Claudiu T Supuran
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

7.  Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.

Authors:  M E J Lean; R Carraro; N Finer; H Hartvig; M L Lindegaard; S Rössner; L Van Gaal; A Astrup
Journal:  Int J Obes (Lond)       Date:  2013-08-14       Impact factor: 5.095

8.  Anti-inflammatory and antimicrobial activities of novel pyrazole analogues.

Authors:  R Surendra Kumar; Ibrahim A Arif; Anis Ahamed; Akbar Idhayadhulla
Journal:  Saudi J Biol Sci       Date:  2015-07-29       Impact factor: 4.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.